New drug shows promise for blistering skin disease, but Long-Term use needed

NCT ID NCT05681481

Terminated Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Feb 26, 2026 · Last updated May 13, 2026 · Updated 16 times

Summary

This study looked at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who completed an earlier study could receive the drug for up to 48 weeks, with the option to pause and restart if symptoms returned. The goal was to see if the drug is safe over time, but it is not a cure—patients may need ongoing treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele

Catania, 95123, Italy
Azienda Sanitaria Di Firenze

Florence, 50125, Italy
Azienda USL Toscana Centro - Ospidale Piero Palagi

Florence, 50122, Italy
Charité - Universitätsmedizin Berlin

Berlin, 10117, Germany
Diagnostic and Consulting Center Aleksandrovska EOOD

Sofia, 1431, Bulgaria
Fakultna nemocnica Trnava

Trnava, 91702, Slovakia
Fakultni nemocnice Bulovka

Prague, 180 00, Czechia
First OC Dermatology

Fountain Valley, California, 92708, United States
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

Milan, 20122, Italy
Fondazione IRCCS Policlinico San Matteo di Pavia

Pavia, 27100, Italy
Fondazione Policlinico Universitario A. Gemelli

Rome, 00168, Italy
Guy's and St Thomas' NHS Foundation Trust

London, SE1 9RT, United Kingdom
Hokkaido University Hospital

Sapporo, 060-8648, Japan
Hospital Of Skin And Venereal Diseases of Thessaloniki

Thessaloniki, 54643, Greece
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Clínico San Cecilio

Granada, 18016, Spain
Hospital Universitario Doctor Peset

Valencia, 46017, Spain
Hospital of Venereal and Skin Diseases A.Syggros

Athens, 16121, Greece
IDI IRCCS - Istituto Dermopatico dell'Immacolata

Roma, 00167, Italy
LMU Klinikum der Universität

München, 80337, Germany
Medical Dermatology Specialists

Phoenix, Arizona, 85006, United States
Miami Dermatology and Laser Institute

Miami, Florida, 33173, United States
Ospedale Policlinico San Martino

Genova, 16132, Italy
Poliklinika Solmed

Zagreb, 10000, Croatia
Premier Specialists

Kogarah, 2217, Australia
Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai, 200025, China
Saint Louis University

St Louis, Missouri, 63110, United States
Semmelweis Egyetem

Budapest, 1085, Hungary
Sheba Medical Center - PPDS

Ramat Gan, 5262100, Israel
The First Affiliated Hospital of Chongqing Medical University

Chongqing, 400016, China
Universitair Medisch Centrum Groningen

Groningen, 9713 GZ, Netherlands
Universitatsklinikum Dusseldorf

Düsseldorf, 40225, Germany
Universitatsklinikum Schleswig-Holstein

Kiel, 24105, Germany
University Clinical Center of Serbia - PPDS

Belgrade, 11000, Serbia
University of Michigan Hospital

Ann Arbor, Michigan, 48109, United States
Universitätsklinikum Carl Gustav Carus an der TU Dresden

Dresden, 01307, Germany
Universitätsklinikum Würzburg

Würzburg, 97080, Germany
Univerzitna nemocnica Bratislava

Bratislava, 821 06, Slovakia
West China Hospital of Sichuan University

Chengdu, 610041, China
Wright State Physicians

Fairborn, Ohio, 45324, United States

Conditions

Explore the condition pages connected to this study.

BULLOUS PEMPHIGOID